Compare JYNT & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JYNT | SCLX |
|---|---|---|
| Founded | 2010 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 149.5M | 139.3M |
| IPO Year | 2014 | N/A |
| Metric | JYNT | SCLX |
|---|---|---|
| Price | $8.79 | $14.08 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 1 |
| Target Price | ★ $17.00 | N/A |
| AVG Volume (30 Days) | ★ 96.2K | 72.9K |
| Earning Date | 11-06-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $54,176,002.00 | $40,360,000.00 |
| Revenue This Year | $6.11 | N/A |
| Revenue Next Year | $6.13 | $749.70 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 10.47 | N/A |
| 52 Week Low | $7.50 | $3.60 |
| 52 Week High | $13.47 | $34.27 |
| Indicator | JYNT | SCLX |
|---|---|---|
| Relative Strength Index (RSI) | 51.18 | 35.68 |
| Support Level | $8.64 | $12.87 |
| Resistance Level | $8.99 | $14.40 |
| Average True Range (ATR) | 0.27 | 0.94 |
| MACD | -0.01 | -0.30 |
| Stochastic Oscillator | 52.74 | 18.92 |
The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The Company has one operating business segment; The Franchise Operations segment which is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue from customers by providing access to the Company's franchise license, which represents symbolic intellectual property.
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.